NAD+ vs Sermorelin: What the Research Shows
NAD+ and Sermorelin side by side: what they are, how they are regulated and what is still unknown.
Where the research points
Consider NAD+ if…
- you want a systematic review of the field: for NAD+ supplementation, clinical effectiveness for anti-aging or wellness outcomes remains inconclusive[11]
- you want to know about intravenous use: the systematic review found no eligible outcomes trials of intravenous or intramuscular NAD+ for anti-aging or wellness[11]
- you want real-world IV data: in a retrospective pilot of commercial infusions, NAD+ IV was associated with moderate to severe gastrointestinal symptoms, higher heart rate and chest pressure[13]
Consider Sermorelin if…
- you want human data in growth-hormone-deficient children, though uncontrolled: Mean height velocity rose from 4.1 cm/yr at baseline to 8.0 cm/yr at 6 months and 7.2 cm/yr at 12 months (open-label, no control group).[12]
What they have in common
- Sermorelin's only FDA record is Geref, listed with marketing status Discontinued[14]
Spec comparison
Showing 9 of 10 fields where the two differ. PCAC vote, Jul 2026 are the same or both unknown.
| Field | NAD+ | Sermorelin |
|---|---|---|
| Class | Coenzyme (injectable, IV or nasal) | GHRH analog |
| Also called | NAD, nicotinamide adenine dinucleotide | — |
| FDA status | Compounded | Compounded by prescription |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | No WADA record in our data | Prohibited by WADA (S2.2.4)Sermorelin is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times. |
| Anti-doping detection | None reportedanti-doping literature, as of 2 Oct 2026 |
|
| Half-life | [half-life by route] | No published half-life foundPubMed search, 11 Oct 2026 |
| Evidence strength | [evidence grade] | Human RCT evidence, 4 of 4Strongest: The Journal of clinical endocrinology and metabolism 1992, PMID 1379256 |
| Human studies we summarised | [n] | 6 human (1 randomized or controlled) of 9 summarised |
| Typical study doses | [dose range] |
|
Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.
NAD+ and Sermorelin together
People also search for this pair as a stack. The stack page covers timing and interaction questions as they are sourced. Evidence for the combination: No studies tested these together (PubMed search: 0 results, 2 Oct 2026).
What the studies measured
In healthy old men, short-term subcutaneous GHRH reversed age-related decreases in GH and IGF-I.[4]
In a later study of nightly GHRH in older men, weight, BMI and DEXA measures of muscle and fat did not change.[6]
A review found no eligible outcomes trials of intravenous or intramuscular NAD+ itself for anti-aging or wellness.[11]
In children with GH deficiency given daily GHRH, mean height velocity rose from 4.1 cm/yr at baseline to 8.0 cm/yr at 6 months and 7.2 cm/yr at 12 months.[12]
On functional, metabolic and vascular outcomes, the same NAD+ review found inconsistent results that often showed no effect or were limited to particular endpoints.[11]
Approval, route and rules
Sermorelin's only FDA record is the discontinued Geref product.[14]
In July 2008 the only US manufacturer of recombinant GHRH announced the discontinuation of Geref.[16]
In a review of clinic NAD+ IV use, moderate to severe symptoms went with longer infusions, averaging 97 min against 37 min for NR IV.[13]
Sermorelin is one of the named examples of GHRH analogues on WADA's prohibited list.[1]
Common questions
Is NAD+ or sermorelin better for anti-aging?
In older men, nightly GHRH did not change weight or DEXA measures of muscle and fat. The NAD+ evidence is covered above.[6]
Can you use NAD and sermorelin together?
No study of the combination is cited here.[13]
Is sermorelin FDA approved like NAD?
Drugs@FDA shows sermorelin only as Geref, marked discontinued.[14]
Sources
- 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 2An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
- 3Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
- 4Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.The Journal of clinical endocrinology and metabolism · 1992PMID 1379256Accessed 2 Oct 2026
- 5Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels.American journal of men's health · 2017PMID 28830317Accessed 2 Oct 2026
- 6Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.Metabolism: clinical and experimental · 1997PMID 9005976Accessed 2 Oct 2026
- 7PubMed search: (sermorelin[tiab] OR Geref[tiab]) (34 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 8PubMed search: (sermorelin[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab] OR "GHRH 1-29"[tiab]) AND (elderly[tiab] OR aging[tiab] OR "older adults"[tiab] OR adults[tiab]) AND (treatment[tiab] OR therapy[tiab] OR administration[tiab]) (15 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 9PubMed search: (sermorelin[tiab] OR Geref[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10PubMed search: ("NAD+"[tiab] OR "nicotinamide adenine dinucleotide"[tiab]) AND (sermorelin[tiab] OR Geref[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 11NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence.Ageing research reviews · 2026PMID 41655607Accessed 2 Oct 2026
- 12Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group.The Journal of clinical endocrinology and metabolism · 1996PMID 8772599Accessed 2 Oct 2026
- 13Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting.Frontiers in aging · 2026PMID 41704678Accessed 2 Oct 2026
- 14Drugs@FDA (openFDA) search: active ingredient "sermorelin"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 15PubMed search: (sermorelin[tiab] OR Geref[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (21 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 16Clinical review: Is lack of recombinant growth hormone (GH)-releasing hormone in the United States a setback or time to consider glucagon testing for adult GH deficiency?The Journal of clinical endocrinology and metabolism · 2009PMID 19509104Accessed 2 Oct 2026
Found an error? Report a correction.